• Arrowhead Pharmaceuticals prepaid its existing $400 million Sixth Street facility at a $68 million discount to the contractual minimum repayment amount.
• New $400 million senior secured term loan priced at 3-month SOFR with a 5.5% margin, versus 15% previously.
• All principal is due November 2, 2031, with no scheduled amortization payments before maturity.
• The new facility eliminates required prepayments from transaction proceeds and commercial revenue.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000879407-26-000063), on November 04, 2026, and is solely responsible for the information contained therein.